José Manuel S.
- Country
- Portugal
- Department
- Pneumology Department
Research Overview
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Subcutaneous Ianalumab (VAY736) Added to Standard Therapy in Systemic Lupus Erythematosus
- A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis
- Long-term Safety and Tolerability Assessment of Ianalumab in Systemic Lupus Erythematosus: A Randomized, Double-blind, Placebo-controlled Extension Study
Data & Insights
Has run more than one trial at 74 of 285 partner sites.
Specializations
Nephrology Research
Specialized in studying progressive non-diabetic chronic kidney disease and its clinical management. Focuses on evaluating innovative therapeutic approaches for kidney disease progression.
- Chronic Kidney Disease Management
- Renal Disease Progression
- Standard of Care Optimization
Investigates novel therapeutic interventions for improving outcomes in patients with chronic kidney conditions.
Therapeutic Innovation
Conducts research on novel therapeutic agents for treating kidney disorders, with particular attention to medication efficacy and safety profiles in adult populations.
- Drug Safety Assessment
- Clinical Efficacy Studies
- Treatment Response Evaluation
Examines the integration of new treatments with established care protocols in nephrology.
Clinical Outcomes
Focuses on analyzing disease progression markers and therapeutic interventions in kidney disorders. Studies the effectiveness of combined treatment approaches.
- Disease Progression Monitoring
- Treatment Response Assessment
- Patient Outcome Analysis
Evaluates comparative effectiveness of different therapeutic strategies in kidney disease management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.